In cancer of the breast or prostate, cancer cells can remain dormant for years and even decades before recurring as metastatic disease.23 During this latent period, patients are considered to be disease-free due
Grade 4 neutropenia occurred in a minority of patients, and Conclusion Anthracyclines and taxanes are considered the most active agents for first-line treatment of women with metastatic breast cancer. Many patients are candidates for third- and fourth-line chemotherapy regimens to palliate symptoms and...
Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2–3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study. lancet Oncol. 2012;13:420–32. Article PubMed Google Scholar Crew KD,...
Monitor patients for signs and symptoms of ILD. Promptly investigate evidence of ILD. Evaluate patients with suspected ILD by radiographic imaging. Consider consultation with a pulmonologist. For asymptomatic ILD/pneumoni...
Monitor for and promptly investigate signs and symptoms including cough, dyspnea, fever, and other new or worsening respiratory symptoms. Permanently discontinue ENHERTU in all patients with Grade 2 or higher ILD/pneumonitis. Advise patients of the risk and to immediately report symptoms. • ...
CTs were used in early lines for patients with visceral symptoms. Introduction Breast cancer (BC) is the most common cancer among women [1, 2]. It is also the second most common cause of cancer-related deaths in women globally [2], and the third leading cause o...
Daiichi Sankyo and AstraZeneca’s ENHERTU® has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received a prior anti-HER2-based regimen either in the metasta...
nature medicine Article https://doi.org/10.1038/s41591-024-03021-7 Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial Received: 29 March 2024 Accepted: 26 April 2024 Published online: 2 June 2024...
Oncological and Oral Sciences, Section of Surgical, University of Palermo, Palermo, Italy Objective: Metastatic breast cancer (MBC) is an incurable disease; the treatment of this disease prolongs survival, improving the quality of life (QoL) with a balance between efficacy and toxicity of the trea...
Breast Cancer Resources Featured Social Media Break In late January 2021 I decided to take a break from social media for the month of February. What I discovered was I needed more than a month away. One month became two and so forth. Although, I am no longer on this break, I do limit...